These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21535158)

  • 1. Xenogeneic immunosuppression of human umbilical cord mesenchymal stem cells in a major histocompatibility complex-mismatched allogeneic acute graft-versus-host disease murine model.
    Guo J; Yang J; Cao G; Fan H; Guo C; Ma YE; Qian Y; Chen L; Li X; Chang C
    Eur J Haematol; 2011 Sep; 87(3):235-43. PubMed ID: 21535158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.
    Prigozhina TB; Khitrin S; Elkin G; Eizik O; Morecki S; Slavin S
    Exp Hematol; 2008 Oct; 36(10):1370-6. PubMed ID: 18619727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model.
    Jeon MS; Lim HJ; Yi TG; Im MW; Yoo HS; Choi JH; Choi EY; Song SU
    Cell Immunol; 2010; 261(1):57-63. PubMed ID: 20004369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease.
    Chen W; Li M; Li Z; Yan Z; Cheng H; Pan B; Cao J; Chen C; Zeng L; Xu K
    Immunol Lett; 2012 Apr; 143(2):161-9. PubMed ID: 22342854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of third-party tolerogenic dendritic cells in the prevention of acute graft-versus-host-disease following allogeneic bone marrow transplantation in mice].
    Li GP; Yang J; Hao J; Yang YM; Ren YN; Xie RF; Fan HH; Qian KC
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):461-6. PubMed ID: 22967381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
    Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
    Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of delayed sequential bone marrow transplantation on acute graft-versus-host disease in major H-2 incompatible mouse transplantation].
    Wang CL; Xu KL; Pan XY; Du B
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):92-6. PubMed ID: 18681308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation.
    Toubai T; Tanaka J; Nishihira J; Ohkawara T; Hirate D; Kondo N; Tone S; Shono Y; Ibata M; Sugita J; Kato N; Miura Y; Iwao N; Ota S; Imamura M
    Transpl Immunol; 2006 Aug; 16(2):117-24. PubMed ID: 16860715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
    Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
    Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.